Aquestive Therapeutics, Inc.

AQST ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017
Operating Activities
Net Income $-8.9M
Depreciation & Amortization $3.8M
Depreciation
Amortization $51.0K
Stock-Based Compensation $0
Net Cash from Operating Activities $5.8M
Investing Activities
Capital Expenditures $2.1M
Business Acquisitions
Net Cash from Investing Activities $-2.1M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $4.4M
Net Change in Cash $8.2M
Free Cash Flow $3.8M
← Newer Page 2 of 2 Older →